Roughly 400 patients who agreed to take cancer detection tests with biotech firm Grail received letters indicating they may have cancer, but the company said the letters were not accurate, blaming it on a “software configuration issue” that caused its telemedicine vendor to send out the incorrect information—a development that’s caused at least one life insurance company to reevaluate its business with the cancer screening firm, according to the Financial Times.
Grail confirmed the issue to Forbes, stating a “software configuration issue” experienced by their telemedicine vendor—PWNHealth—resulted in the error and that more than half of the patients affected had not yet had their blood drawn for the Galleri test.
PWNHealth spokeswoman Megan Koehler said that upon becoming aware of the matter, the company identified a misconfiguration of its patient engagement platform used to send templated communications—adding it implemented processes to avoid the issue from happening again.
Grail promptly informed affected patients of the error by phone and email after the letters were sent, according to a spokeswoman Trish Rowland.
PWNHealth’s outreach to patients was conducted in partnership with Grail within 36 hours of the software issue, Koehler said.
Full Link ( Here )
© CopyRights RawNews1st
